trending Market Intelligence /marketintelligence/en/news-insights/trending/T9fLOTtxENTXJGLAN5K0Zg2 content esgSubNav
In This List

Therapix Biosciences CFO steps down

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Therapix Biosciences CFO steps down

Therapix Biosciences Ltd.'s CFO Josh Blacher agreed to step down under a mutually amicable separation agreement, effective Dec. 19.

Blacher was appointed Therapix Biosciences' CFO in May 2017.

The company said it was searching for a new CFO and Blacher will support an orderly transition of his overall responsibilities to his replacement.